Sign In
Buy BCRX
$8.25
-0.0900 (-1.08%)
At Close: Jun 03, 2026
Fisher Asset Management LLC Lowers Stake in BioCryst Pharmaceuticals, Inc. $BCRX
04:36am, Wednesday, 03'rd Dec 2025
Fisher Asset Management LLC decreased its position in BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) by 8.8% during the second quarter, according to the company in its most recent disclosure with the S
Astria Therapeutics: Updating Target Price, Biocryst Deal Expected To Go Through, Hold
01:29am, Sunday, 30'th Nov 2025
I maintain a hold rating on Astria Therapeutics with an updated $13 target price following Biocryst's announced acquisition, expecting a 90%+ chance of deal closure by Q1 2026. The investment thesis s
BioCryst Pharmaceuticals (NASDAQ:BCRX) vs. Merck KGaA (OTCMKTS:MKKGY) Financial Contrast
02:46am, Wednesday, 26'th Nov 2025
Merck KGaA (OTCMKTS:MKKGY - Get Free Report) and BioCryst Pharmaceuticals (NASDAQ: BCRX - Get Free Report) are both medical companies, but which is the better investment? We will compare the two busin
BioCryst Pharmaceuticals, Inc. (BCRX) Presents at Jefferies London Healthcare Conference 2025 Transcript
02:23pm, Monday, 24'th Nov 2025
BioCryst Pharmaceuticals, Inc. ( BCRX ) Jefferies London Healthcare Conference 2025 November 19, 2025 12:00 PM EST Company Participants Jon Stonehouse - CEO & Executive Director Charles Gayer - Presid
– Findings highlight negative psychosocial impact of HAE attacks and resulting ED/hospital visits on pediatric patients and their caregivers – – ORLADEYO oral granules demonstrated early an
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
07:01am, Wednesday, 05'th Nov 2025
RESEARCH TRIANGLE PARK, N.C., Nov. 05, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst's board of directors granted t
BioCryst to Present at Upcoming Investor Conference
07:00am, Wednesday, 05'th Nov 2025
RESEARCH TRIANGLE PARK, N.C., Nov. 05, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company plans to present at the Jefferies Global Healthcare Conf
BioCryst Pharmaceuticals, Inc. (BCRX) Q3 2025 Earnings Call Transcript
12:16pm, Monday, 03'rd Nov 2025
BioCryst Pharmaceuticals, Inc. ( BCRX ) Q3 2025 Earnings Call November 3, 2025 8:30 AM EST Company Participants Nick Wilder Jon Stonehouse - CEO & Executive Director Charles Gayer - President & Chief
BioCryst Reports Third Quarter 2025 Financial Results and Provides Business Update
07:00am, Monday, 03'rd Nov 2025
—Q3 2025 ORLADEYO net revenue of $159.1 million (+37 percent y-o-y)— —Q3 2025 operating profit of $29.6 million (+285 percent y-o-y); non-GAAP operating profit of $51.7 million (+107 percent y
BioCryst Pharmaceuticals (BCRX) Earnings Expected to Grow: Should You Buy?
11:00am, Monday, 27'th Oct 2025
BioCryst (BCRX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
BioCryst to Present New Pediatric HAE Data at the American College of Allergy, Asthma & Immunology 2025 Annual Scientific Meeting
07:00am, Thursday, 23'rd Oct 2025
RESEARCH TRIANGLE PARK, N.C., Oct. 23, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present four abstracts at the Annual Scientific Mee
BioCryst to Report Third Quarter 2025 Financial Results on November 3
07:00am, Monday, 20'th Oct 2025
RESEARCH TRIANGLE PARK, N.C., Oct. 20, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its third quarter 2025 financial results on
NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale
BioCryst (BCRX) Soars 6.1%: Is Further Upside Left in the Stock?
09:01am, Thursday, 16'th Oct 2025
BioCryst (BCRX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Astria Therapeutics Stock Rallies 37% on $700M Buyout Offer From BCRX
11:06am, Wednesday, 15'th Oct 2025
ATXS stock jumps 37% after agreeing to a $700 million cash-and-stock buyout by BioCryst, boosting the latter's HAE treatment pipeline.
